BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 34404075)

  • 1. [Alectinib for an Octogenarian Patient with Poor Performance Status and ALK Fusion Gene-Positive Lung Cancer-A Case Report].
    Kamiyoshihara M; Igai H; Matsuura N; Yazawa T; Ohsawa F
    Gan To Kagaku Ryoho; 2021 Aug; 48(8):1053-1055. PubMed ID: 34404075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Gefitinib Monotherapy Afforded Long-Term Survival of an Octogenarian Patient with a Postoperative Recurrence of a Pulmonary Adenocarcinoma-A Case Report].
    Kamiyoshihara M; Igai H; Ohsawa F; Numajiri K
    Gan To Kagaku Ryoho; 2023 Feb; 50(2):187-189. PubMed ID: 36807168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
    Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
    Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Erlotinib plus Bevacizumab Therapy for Postoperative Recurrence of Adenosquamous Cell Carcinoma Harboring EGFR Mutation-A Case Report].
    Kamiyoshihara M; Yazawa T; Igai H; Matsuura N; Ohsawa F; Furusawa S
    Gan To Kagaku Ryoho; 2021 Jun; 48(6):841-843. PubMed ID: 34139736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature.
    Mamesaya N; Nakashima K; Naito T; Nakajima T; Endo M; Takahashi T
    BMC Cancer; 2017 Jul; 17(1):471. PubMed ID: 28683775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The case of double primary lung adenocarcinomas with an EGFR mutation and ALK translocation successfully treated with alectinib at the post-surgical recurrence.
    Tsunezuka Y; Tanaka N; Fujimori H; Togashi Y; Baba S; Takeuchi K; Katayanagi K; Kurumaya H; Kitade H; Atagi S; Yano S
    J Med Invest; 2017; 64(3.4):305-307. PubMed ID: 28955002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
    Watanabe S; Hayashi H; Okamoto K; Fujiwara K; Hasegawa Y; Kaneda H; Tanaka K; Takeda M; Nakagawa K
    Clin Lung Cancer; 2016 Nov; 17(6):528-534. PubMed ID: 27318655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A Pulmonary Mucoepidermoid Carcinoma with Anaplastic Lymphoma Kinase Fusion Responding to Alectinib Hydrochloride].
    Onodera K; Sato N; Kobayashi K; Kurotaki H
    Kyobu Geka; 2019 Oct; 72(11):889-892. PubMed ID: 31588102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful oral desensitization against skin rash induced by alectinib in a patient with anaplastic lymphoma kinase-positive lung adenocarcinoma: A case report.
    Shirasawa M; Kubotaa M; Harada S; Niwa H; Kusuhara S; Kasajima M; Hiyoshi Y; Ishihara M; Igawa S; Masuda N
    Lung Cancer; 2016 Sep; 99():66-8. PubMed ID: 27565916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring non-EML4-ALK rearrangements detected from cerebrospinal fluid: A case report.
    Li Z; Li P; Yan B; Gao Q; Jiang X; Zhan Z; Yan Q; Lizaso A; Huang C
    Thorac Cancer; 2020 Jan; 11(1):176-180. PubMed ID: 31766077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement-positive non-small cell lung cancer treated with alectinib.
    Yamamoto Y; Okamoto I; Otsubo K; Iwama E; Hamada N; Harada T; Takayama K; Nakanishi Y
    Invest New Drugs; 2015 Oct; 33(5):1148-50. PubMed ID: 26334220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid and dramatic response to alectinib in an anaplastic lymphoma kinase rearranged non-small-cell lung cancer patient who is critically ill.
    Yoshida T; Hida T; Yatabe Y
    Anticancer Drugs; 2016 Jul; 27(6):573-5. PubMed ID: 26938871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
    Hida T; Nokihara H; Kondo M; Kim YH; Azuma K; Seto T; Takiguchi Y; Nishio M; Yoshioka H; Imamura F; Hotta K; Watanabe S; Goto K; Satouchi M; Kozuki T; Shukuya T; Nakagawa K; Mitsudomi T; Yamamoto N; Asakawa T; Asabe R; Tanaka T; Tamura T
    Lancet; 2017 Jul; 390(10089):29-39. PubMed ID: 28501140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EML4-ALK positive lung adenocarcinoma with skeletal muscle metastasis in the right calf which was treatable with lorlatinib after resistance to treatment with alectinib.
    Matsuda H; Hara M; Iwakami SI; Takahashi K
    BMJ Case Rep; 2021 Apr; 14(4):. PubMed ID: 33906872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alectinib: a review of its use in advanced ALK-rearranged non-small cell lung cancer.
    McKeage K
    Drugs; 2015 Jan; 75(1):75-82. PubMed ID: 25428710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.
    Ou SH; Greenbowe J; Khan ZU; Azada MC; Ross JS; Stevens PJ; Ali SM; Miller VA; Gitlitz B
    Lung Cancer; 2015 May; 88(2):231-4. PubMed ID: 25736571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leptomeningeal recurrence after long-term alectinib therapy for non-small cell lung cancer harboring an EML4-ALK fusion protein.
    Kawamura T; Murakami H; Kobayashi H; Nakashima K; Omori S; Wakuda K; Ono A; Kenmotsu H; Naito T; Endo M; Takahashi T
    Invest New Drugs; 2019 Feb; 37(1):184-187. PubMed ID: 29971546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival Analysis for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status Treated with Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401.
    Iwama E; Goto Y; Murakami H; Tsumura S; Sakashita H; Mori Y; Nakagaki N; Fujita Y; Seike M; Bessho A; Ono M; Nishitsuji M; Akamatsu H; Morinaga R; Akagi T; Shimose T; Tokunaga S; Yamamoto N; Nakanishi Y; Sugio K; Okamoto I
    Oncologist; 2020 Apr; 25(4):306-e618. PubMed ID: 32297438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary Adenocarcinoma, Harboring Both an EGFR Mutation and ALK Rearrangement, Presenting a Stable Disease to Erlotinib and a Partial Response to Alectinib.
    Yokoyama A; Tamura A; Miyakawa K; Kusaka K; Shimada M; Hirose T; Matsui H; Kitani M; Hebisawa A; Ohta K
    Intern Med; 2018 Aug; 57(16):2377-2382. PubMed ID: 29526950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alectinib is effective, safe and tolerable in an adolescent with stage IVB ALK-rearranged adenocarcinoma of the lung.
    Balzer BWR; Loo C; Wegner EA; Nath CE; Lee S; Smith C; Lewis CR; Trahair TN; Anazodo AC
    Pediatr Hematol Oncol; 2018; 35(7-8):415-421. PubMed ID: 30526220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.